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Abstract
While the entirety of ‘Chemical Space’ is huge (and assumed to contain between 1063 and 10200 ‘small molecules’), distinct
subsets of this space can nonetheless be defined according to certain structural parameters. An example of such a subspace
is the chemical space spanned by endogenous metabolites, defined as ‘naturally occurring’ products of an organisms’
metabolism. In order to understand this part of chemical space in more detail, we analyzed the chemical space populated
by human metabolites in two ways. Firstly, in order to understand metabolite space better, we performed Principal
Component Analysis (PCA), hierarchical clustering and scaffold analysis of metabolites and non-metabolites in order to
analyze which chemical features are characteristic for both classes of compounds. Here we found that heteroatom (both
oxygen and nitrogen) content, as well as the presence of particular ring systems was able to distinguish both groups of
compounds. Secondly, we established which molecular descriptors and classifiers are capable of distinguishing metabolites
from non-metabolites, by assigning a ‘metabolite-likeness’ score. It was found that the combination of MDL Public Keys and
Random Forest exhibited best overall classification performance with an AUC value of 99.13%, a specificity of 99.84% and a
selectivity of 88.79%. This performance is slightly better than previous classifiers; and interestingly we found that drugs
occupy two distinct areas of metabolite-likeness, the one being more ‘synthetic’ and the other being more ‘metabolite-like’.
Also, on a truly prospective dataset of 457 compounds, 95.84% correct classification was achieved. Overall, we are confident
that we contributed to the tasks of classifying metabolites, as well as to understanding metabolite chemical space better.
This knowledge can now be used in the development of new drugs that need to resemble metabolites, and in our work
particularly for assessing the metabolite-likeness of candidate molecules during metabolite identification in the
metabolomics field.
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Introduction
The area of ‘Metabolomics’ is relatively young [1,2] and
describes the large-scale analysis of (often human and endogenous)
metabolites. It comprises both the analytical approaches em-
ployed, such as mass spectroscopy (MS) as well as the analysis of
the resulting data on a network- and phenotype level. Metabo-
lomics is a particularly interesting research field as it allows the
determination of biological phenotypes on a chemical basis, since
endogenous metabolites are closer phenotype of an organism than
for example gene expression [3]. As a consequence, new
knowledge on biological processes can be obtained by investigating
metabolites.
Various experimental techniques, most commonly MS and
nuclear magnetic resonance (NMR), have been devised to detect
and identify metabolites, with different approaches being
necessary to cover different parts of the metabolite spectrum. In
practice it is found that some metabolites with different
lipophilicity can only be detected by one of the experimental
techniques but not by others [4–9]. Different techniques might
also be used depending on the type and quantity of sample to be
analyzed, as well as the concentration and the molecular
properties of the metabolites. In general terms, NMR allows for
a detailed characterization of the chemical structure of the
(un)known compound, and it is the preferred technique for
unambiguous identification of a chemical structure. On the
downside, NMR requires abundant and pure sample, yielding
low sensitivity. Conversely, MS offers high sensitivity and
specificity, requiring less amounts of sample, but providing less
information about the chemical structure, namely its elemental
composition and some structural fragments.
However, despite its ability to describe a phenotype in many
cases in a more relevant manner than other approaches, in
metabolomics studies a major challenge exists, namely metabolite
identification [10–12]. While many endogenous metabolites can
be detected (and their spectrum determined), also elucidating their
chemical structures is essential to properly interpret results, and to
utilize the analytical data to finally answer biological questions
[13]. However, the step from the analytical readout to the
structural formula is often fraught with problems.
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In the commonly employed MS-based profiling approaches
(which are also used in our group), once metabolites are detected
their elemental composition (or multiple elemental compositions)
[14,15] can be derived directly from MS data. Based on this
elemental composition, matching chemical structures can be
proposed following two approaches. In the first approach,
molecular databases are queried for the presence of molecules
with the same elemental composition (or similar spectral data), and
hits are returned as candidate structures [13,16]. However, the
major shortcoming of this approach is that one can only find in
databases what has been found before, making the elucidation of
novel metabolites impossible. In the second approach, which is
meant to cover this shortcoming, the elemental composition and
optionally other experimental data are provided to a ‘structure
elucidator’, which will generate in silico all possible chemical
structures which match the analytical constraints provided to the
algorithm [17–19]. While one of the structures generated will be
the metabolite of interest, depending on the elemental formula
provided, the latter method in particular yields a large number of
possible solutions. (For example, the elemental composition of
phenylalanine, C9H11NO2, yields 277,810,163 possible candi-
date structures.)
Due to the above reasons, molecular databases compiling
structural information on endogenous metabolites are currently
limited in size and they certainly do not cover metabolite space
exhaustively. The number of possible metabolites is yet unknown
[20]. While lipids alone are estimated to exist in the order of
20,000 different structures [21] plants are thought to contain
around 200,000 metabolites [3]. Given these figures, the
experimental data obtained until today is relatively scarce. A
large database of metabolites such as the Human Metabolome
Database (HMDB) [21] contains in its current version about 8,000
structures, which is only a fraction of the above numbers. Still,
HMDB is the most comprehensive dataset to represent the
Metabolite Space from a human point of view. Plant metabo-
lomics makes use of different databases [12]. In addition
metabolomics databases exist [22] that contain metabolites and
the enzymatic reactions that connect them to pathways, such as in
KEGG [23]; some databases contain metabolites grouped by
organism such as in BioCyc [24] and other database relate
metabolites with experimental information, such as Metlin [25].
Still, given its number of data entries, the approach to match the
MS or NMR spectrum to database spectra can only succeed in a
fraction of cases.
Hence, solutions need to be ranked, based on the likelihood of a
molecular structure to be a metabolite [26] – and, as we will
outline in more detail below, this is one of the main aims of the
current work of implementing a ‘metabolite-likeness’ model. In
addition, our goal was to understand metabolites better from a
chemical point of view, and this is what we will discuss in the
remainder of this work, after setting our approach in context with
the ‘prior art’ in the field of metabolite classification.
Focusing on metabolites of E. coli, Nobeli et al. [27] studied 745
metabolites of this organism by analyzing physiochemical
descriptors, the diversity of scaffolds, and similarity-based
compound clustering. It was observed that most of the E. coli
metabolites are found between the 100 and 300 Da molecular
weight region, that they contain up to 20 heavy atoms, and that
they are mostly hydrophilic. In addition the low diversity of
molecular scaffolds was observed. The clustering analysis per-
formed revealed that it is difficult to use molecular similarity to
group metabolites in ‘sub-classes’, since there is not a natural
separation according to their two-dimensional structure similarity,
concluding that the metabolite space of E. coli is homogeneous.
While Nobeli et al. focused on the metabolome of E. Coli, Gupta
et al. [28] represented the chemical space of metabolites using the
KEGG/LIGAND database, which includes metabolites from
different species as well as xenobiotics. The chemical space of
non-metabolites was approximated by ZINC database [29], which
contains small molecules that are commercially available. These
molecules are often used as the search space, in virtual-screening
research, or as background set in classification projects.
In this work it was concluded that hydroxyl groups, aromatic
systems, and molecular weight are discriminating features between
metabolite and non-metabolite chemical space. Furthermore, Self
Organizing Maps (SOM), Random Forests (RF), and Classifica-
tion Trees (CT) were employed to distinguish between the two
classes of compounds, which were represented by 3D descriptors,
topological descriptors, and global molecular descriptors, respec-
tively. The best classification accuracy was 97%, achieved by the
combination of RF and global molecular descriptors. (No external
validation of such models is reported in their work, as opposed to
our novel study, which includes a prospective validation set.)
While trying to discriminate metabolites from non-metabolites
was the obvious starting point, it was then noted that also bioactive
compounds, notably drugs, could be related to the metabolite/
non-metabolite chemical spaces. All three of those sets were hence
analyzed by Dobson et al. in a subsequent study [30]. Endogenous
metabolites were selected from the HMDB, BioCyc, BiGG, and
Edinburgh databases while drugs were compiled from DrugBank
and KEGG DRUG. In addition, screening molecules from ZINC
were the source for the background compound set. Molecules were
represented using connectivity and path fingerprints, MDL Public
Keys and E-state, and the similarity between them was determined
by the Tanimoto coefficient. In this work the authors concluded
that drugs are more similar to metabolites than to screening compounds.
Furthermore the distribution of molecular properties among the
different families of compounds was studied and it was noticed that
metabolites tend to have fewer heavy atoms than the other two
groups of compounds. Another relevant physicochemical property
identified was lipophilicity, which showed a bias in metabolites
towards hydrophilicity, whereas drugs and screening compounds
were more hydrophobic.
In the current study we are extending previous work by,
compared to Gupta et al., focusing on a large set of human
metabolites obtained from HMDB, instead of metabolites from
multiple species, and an updated collection of background
compounds from ZINC. We make use of different molecular
descriptors such as ECFP_4 [31], FCFP_4, MDL Public Keys
[32], and physicochemical properties, as well as classifiers like
Support Vector Machines (SVM) [33], Random Forest (RF) [34]
and Naı¨ve Bayes (NB) [35] and evaluate their applicability to
distinguishing metabolites from non-metabolites. In addition we
include a prospective validation set to further assess model
performance. Furthermore, Dobson et al. used molecular
similarity to metabolites as an indicator of metabolite-likeness. In
comparison, we assign our score based on the predictions given by
different classification methods. The classifier presented here
employs, at the time of publication, the most comprehensive
collection of human metabolites and purchasable compounds.
Furthermore we also make use of PCA and hierarchical clustering
to understand which physicochemical properties as well as
chemical functionalities are characteristic of metabolites, and
discriminate them from non-metabolites. The principal aim of this
work is to establish a reliable metabolite classifier for candidate
structures that need to be identified in metabolomics studies;
however, apart from the classifier itself, also understanding
metabolite space better was a second major aim of this work.
Metabolite Space and Metabolite-Likeness
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Methods
Datasets and Data Preprocessing
The Human Metabolome Database (HMDB) version 2.5 [21]
served as source of the metabolite set. This database contains, in
its original form, 7,886 human metabolites as determined by
experimental analytical methods. The ZINC Database (ZINC)
release 8 [29] was chosen to represent non-metabolite chemical
space. From the different datasets provided by ZINC, we selected
the subset ‘‘everything #10’’ (date 2010-06-17), since it includes
21.6 million compounds and it was the largest set at the time, and,
hence, most representative of ‘all’ chemical space.
Molecules from the two datasets were standardized with
PipelinePilot Student Edition 6.1 [36] using the ‘washing’
workflow suggested by Dobson et al. [30], which involved the
selection of the largest fragment in the structure, the removal of
salts and hydrogen atoms and the standardization of charges and
stereochemistry. Because the ZINC database mainly contains
molecules with a low molecular weight, a value of 1000 Daltons
was set as the maximum molecular weight of any compound,
metabolite or not, in this study. While this removes part of
chemical space from the metabolite dataset, this step was necessary
to avoid molecular weight to appear as a major discriminant
between metabolites and non-metabolites (which would not be
relevant in the context of our future application of distinguishing
metabolites from non-metabolites in cases of structures with an
identical sum formula). Furthermore, when employing fingerprints
for classification, the chemical distribution of features (as opposed
to the molecular weight) will be used for classification, hence
making the classification (in this feature space) size-independent.
This filter removed 775 metabolites from the HMDB dataset.
Furthermore, the constraint imposed on molecules to contain
three or more atoms (in order to retain only small organic
molecules in the dataset) removed 65 small molecules and ions
from HMDB. Metabolites from HMDB that are considered drugs
were also removed from the dataset, based on annotations as drugs
in the fields ‘‘Taxonomy Family’’ and ‘‘Taxonomy Sub Class’’
provided by HMDB, removing 92 drugs from the dataset and
reducing the metabolite dataset to 6,954 molecules. The number
of molecules contained in ZINC was excessively large to perform
clustering and classification, concerning the computational
resources needed for such tasks, therefore selecting a subset was
necessary. Such a subset was randomly selected from ZINC, which
contained 194,350 molecules. All of these molecules passed the
filtering based on molecular weight and the minimum number of
atoms. The last dataset preprocessing step was the removal of
metabolites (molecules contained in the HMDB database) from the
ZINC dataset, where 8 molecules were removed from the non-
metabolite set.
Training and Test Sets
Diversity selection [37,38] was used in this work to prepare
representative compound datasets for metabolites and non-
metabolites with the intention of reducing the bias that
overrepresented families of molecules could have on the
classification step. This initially appeared particularly crucial since
lipids were hugely overrepresented in the HMDB database. After
giving it more thought it was noted that this step certainly involves
subjective elements since it, on the one hand, removes information
about the distribution of data points in the original set. On the
other hand, we assumed that there was a significant bias present in
particular in the metabolite dataset not only due to ‘natural’
causes, but also due to the bias introduced by experimental
techniques (such as MS and NMR), which are able to detect and
identify compounds rather selectively. Hence, we came to the
conclusion that close analogues should be removed carefully from
the dataset. In this spirit, each dataset was independently
clustered using the maximal dissimilarity partitioning algorithm
implementation from the ‘Cluster Molecules’ component from
PipelinePilot Student Edition 6.1 [36]. Molecules were repre-
sented by ECFP_4 fingerprints and the distance between each
pair of molecules was calculated using the Tanimoto coefficient.
The maximum dissimilarity of a cluster member to the cluster
centre was 0.6, (that is, molecules from the same cluster possess a
ECFP_4/Tanimoto similarity of at least 0.4). Finally cluster
centers were selected as representatives of each cluster, which
yielded 532 representatives for HMDB and more than 12,000 for
ZINC. In order to have balanced training datasets for model
building (where some algorithms are prone to majority class
predictions), 532 random molecules were selected from ZINC.
These two subsets of 532 molecules each were used for building
the classification models. While these datasets are small, they
were intended to remove much of the bias present in the original
datasets. We also still made use of the additional compound
information available since from the remaining molecules not
included in the training datasets the test set was built, where the
remaining 6,422 metabolites as well as 6,422 randomly selected
non-metabolites were joined to form an initial test set of 12,844
molecules. Hence, this very large test set was used to evaluate
whether model generation with our training dataset assembled in
the way just described would produce viable metabolite-likeness
models.
Prospective Validation Sets
Predictive models are meant to be applied to novel, unseen
molecules, and to estimate the performance on those new
molecules the utilization of external validation sets is crucial. In
order to determine prospective performance of our model, an
external validation set was compiled, which includes 563
metabolites not yet part of HMDB (which were provided by the
database curators). After filtering using the standardization
protocol described above, the resulting prospective validation set
contained 457 metabolites that were not included in any of the
previous preprocessing steps (diversity selection, model building,
and model evaluation). Furthermore, two other datasets of
molecules were assembled for evaluation with the metabolite-
likeness model, namely one of drugs, and one of bioactive
compounds (as determined by experimental assays). To represent
drugs DrugBank release 2.5 (date 23-11-2010) [39] was used,
comprising 6,532 molecules. To represent bioactive molecules,
ChEMBL [40] release 8 (date 09-12-2010) was employed. Both
datasets were normalized using the protocol described above and
from the 635,933 compounds in ChEMBL, 6,312 were randomly
selected (the DrugBank dataset was used in full due to its smaller
size). With these datasets we evaluated if our metabolite-likeness
model is able to detect the biogenic bias of drugs and bioactive
compounds in general. With these three prospective validation sets
(external validation set, drug set, bioactive compound set) we
evaluated our best model, as derived in the parameter exploration,
in two different ways. Firstly, the quality of the predictions for
metabolites that were not involved at any stage of the model
creation by employing an external validation set, was determined.
Secondly, we tested the hypothesis that drugs (and, possibly to a
lesser extent, bioactive molecules) are more similar to metabolites
than to non-metabolites. This hypothesis could either be rejected
or not from the distribution of metabolite-likeness scores as
assigned by our model.
Metabolite Space and Metabolite-Likeness
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Molecular Descriptors
Molecular descriptors should be chosen with care depending
for which problem they are going to be used [41,42]. In this
case different descriptor sets were used for classification as
follows.
a) Atom Counts and Physicochemical Molecular
Descriptors. Atom counts and physicochemical descriptors
are rather simple, intuitive and easy to interpret by chemists. On
the downside, they usually result in poorer classification results
than more complex descriptors since no structural information is
captured. In this study our descriptor set based on atom counts
was called ‘Atom Counts’ and contained counts of the most
common atom types in metabolites, namely H_Count, C_Count,
N_Count, O_Count, F_Count, P_Count, S_Count, Cl_Count.
‘Atom Counts’ descriptors were computed using the component
‘Element Count’ from PipelinePilot Student Edition 6.1 [36].
The physicochemical properties used were the Atom Counts
descriptors mentioned above together with the following
properties: the number of atoms (Num_Atoms in PipelinePilot),
a calculated logP value (ALogP), a calculated logD value (LogD),
the number of hydrogen donors (Num_H_Donors) and acceptors
(Num_H_Acceptors), the number of rotatable bonds
(Num_RotatableBonds), the number of rings (Num_Rings), the
number of aromatic rings (Num_AromaticRings), a calculated
value of solubility (Molecular_Solubility), a calculated value of the
polar surface area (Molecular_PolarSurfaceArea), and a calculated
value for the minimized energy (Minimized_Energy). All these
properties, listed in detail in Table 1, were calculated with the
components ‘Element Count’, ‘Calculate Properties’, ‘ALogP’,
‘LogD’, ‘Surface Area and Volume’, ‘Molecular Energy’ as
implemented in PipelinePilot Student Edition 6.1 [36].
b) Fingerprints. 2D ECFP_X and FCFP_X are ‘‘Extended
Connectivity’’ molecular fingerprints where features are
descriptions of the neighborhood of the atoms up to a certain
distance or radius X. In the ECFP fingerprint the atom identifier is
based on the atom type, while in FCFP it is based on the functional
class of the atom [31]. In this work, ECFP and FCFP fingerprints
with radius 4 were calculated using the component ‘Molecular
Properties’ in PipelinePilot Student Edition 6.1 [36] with the
parameter ‘Convert Fingerprint To’ set to ‘Leave As-Is’. These
fingerprints can produce thousands of features for a molecular
library, including features that are present in very few molecules,
which can easily lead to over fitting. Hence, we folded the
fingerprints to a fixed length of 1024 bits, using PipelinePilot
Student Edition 6.1 [36] component ‘Convert Fingerprint’, to an
output format of ‘Fixed length Array of Bits’, ‘Fixed Bit Length’ of
1024, and ‘Output Bit Order’ of ‘Pack Least-Significant First’.
MDL keys [32] were used as well for classification. MDL Public
Keys are a key-based molecular representation defined by the
presence or absence of 166 predefined keys, or molecular
substructures. Since the size of this key set is only 166 bits, folding
is not necessary.
Principal Component Analysis
Principal Component Analysis (PCA) is a mathematical
transformation that projects the dataset onto a lower dimension
defined by uncorrelated variables, the so-called ‘principal
components’ [43]. Such components are ordered according to
the percentage of variance in the dataset that they explain, which
means that the first principal component explains the highest
variance. We performed a PCA on the training set of metabolites
and non-metabolites in order to understand better the nature of
the chemistry contained in both classes. PCA was performed using
the R library FactoMineR [44] and data was standardized to unit
variance before analysis.
Hierarchical Clustering
Hierarchical Clustering groups objects together that are close in
the particular representation chosen and assigns a hierarchy to the
resulting clusters. This grouping can be agglomerative, where
initially each object is a cluster by itself and where clusters are
subsequently combined, or divisive, where the whole dataset is
assigned to a single cluster initially which is then iteratively split
into smaller clusters. Furthermore, two other factors determine the
output of the clustering, the distance metric between objects and
the method used to link two clusters, i.e. the method used to
calculate the distance between clusters. We have used the
agglomerative hierarchical clustering offered by FactoMineR [44]
on the results of the PCA as described above in combination with
an Euclidean distance metric and Ward’s linkage method. Finally,
the hierarchy of clusters is presented on a dendogram that needs to
be cut at some point to split the clusters. The criteria employed to
cut the dendogram was the default in FactoMineR, which splits the
clusters at the point of maximal loss of intra-cluster inertia. The
clustering results are used to evaluate if some natural grouping
emerges from the data; in our case, whether metabolite space
actually contains several distinct subspaces.
Classification Trees
Classification trees are machine-learning methods that use a
univariate partition to split the dataset in subsets [45]. At each step
the data is split using the predicting variable that optimizes a
certain criteria. In our case, we make use of conditional inference
trees (CIT) as implemented in the R package party [46].
Conditional inference trees perform a covariate selection that
relies on permutation tests and statistical significance. Applying
CIT to a two-class classification problem can be seen as a binary
tree where at each node the dataset is split into two subsets using
the covariate that has the strongest association to the response
variable. In the case that features are binary fingerprints, the
presence or absence of a given feature determines the data split
performed. Variables are selected if they maximize the ‘purity’ of
the split, this is, that each subset contains mostly objects of one
class. The result is a tree that depicts the best variables to split the
data and provides information about relevant variables for each
Table 1. List of atom counts and physicochemical properties used to describe the molecules of this study.
Descriptors Properties
Atom Counts H_Count, C_Count, N_Count, O_Count, F_Count, P_Count, S_Count, Cl_Count
PP_desc Atom Counts, Molecular_Weight, Num_Atoms, ALogP, LogD, Num_H_Donors, Num_H_Acceptors, Num_RotatableBonds, Num_Rings,
Num_AromaticRings, Molecular_Solubility, Molecular_PolarSurfaceArea, Minimized_Energy
PP_desc include Atom Counts and the listed physicochemical properties.
doi:10.1371/journal.pone.0028966.t001
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class of objects. In the course of the present study, classification
trees were applied particularly to ECFP_4 fingerprints, in order to
determine which features distinguish metabolite space from non-
metabolite space.
Fragment Analysis
In this part of the work, we further analyzed the fragment
composition of metabolite and ‘purchasable chemistry’ spaces as a
means to better understand the composition of (and differences
between) both compound spaces. From the point of view of a
chemist, molecular fragments are easier to interpret and convey
more meaning than a fingerprint or a sensitivity percentage.
Therefore we used the component ‘Generate Fragments’ from
PipelinePilot Student Edition 6.1 [36] to enumerate (in PipelinePilot
terminology) rings, ring assemblies, bridge assemblies, chains, and
Murcko assemblies (scaffolds that contain ring systems and ring
systems connected by linkers, but no side chains) [47]. The top 20
most frequent fragments from our two datasets, human metabolites
and purchasable compounds were collected and analyzed.
Machine Learning
Three machine-learning algorithms were used to generate the
models of metabolite-likeness, namely Support Vector Machines
(SVM) [33], Random Forests (RF) [34], and the Naı¨ve Bayes
Classifier (NB) [48]. We used the implementations of these
algorithms in the statistical software package R [49]. For SVM, we
employed the library e1071 [50], which is an implementation of
the standard C++ libsvm [51]. As for RF, we opted for the library
randomForest [52], an R port of the original code of Breiman [34].
Again e1071 was the library chosen for NB.
SVM is one of the most robust and widely used algorithms in
machine learning and it belongs to the class of maximum margin
classifiers [33,53]. In a two-class problem, SVM tries to define a
boundary that maximizes the separation between the two classes.
Provided the classes are linearly separable, SVM builds a
hyperplane with a maximal margin to neighboring objects of the
two classes. When the linear separation is not feasible, a kernel
function executes a nonlinear mapping of the data to a higher
dimension where it can be linearly separated. SVM requires the
tuning of two metaparameters, gamma, which regulates the level
of non-linear behavior of the kernel, and C, the cost of violating
the constraints, in order to achieve an optimal performance. The
kernel type was set to the default Gaussian Radial Basis Function
(RBF). SVMs have been successfully used in molecular classifica-
tion before, such as for classifying ‘drug-likeness’ [54,55].
RF is an ensemble of classification trees [34] in which each tree
classifies, or votes, the class of an object given a randomly chosen
subset of the full variable set. Many of such trees are grown (as
determined by the variable ntree) and majority voting is used to
obtain one final classification result. RF requires the tuning of the
metaparameter mtry, which determines the number of variables
randomly sampled.
The last classification algorithm is the Naı¨ve Bayes algorithm
[48], which relies on the assumption that the variable values are
conditionally independent of the class label. This strong
assumption usually does not hold, but in practice this approach
still allows building good models for multidimensional data, as was
shown for bioactivity datasets before [56,57]. Compared to SVM
and RF, NB only requires one parameter to be tuned, the cut-off
value for the class membership probability (equivalent to changing
the choice of the ‘prior’), which was however not explored in this
work and it was set to its theoretical optimum (it was set to 50% in
the case of balanced datasets, as proposed previously) [58].
According to this, a molecule with a predicted metabolite-likeness
of 50% of higher is considered to be a metabolite, and with less
than 50% metabolite-likeness, a non-metabolite.
Cross Validation and Model Generation
Concerning RF and SVM, k-fold cross validation [59–61] is a
recommended method to tune metaparameters and avoid over
fitting. We opted to apply a 5 fold cross validation, a previously
recommended value for k [62,63], to the 1,064 molecules in the
training dataset. In the case of RF, for each cross validation split a
range of values for mtry metaparameter were tested, while the
number of trees in the forest, ntree, was set to the default value of
500. The mtry giving the highest averaged Area Under the Curve
(AUC) and smallest classification error was chosen as the optimal
value for building the model. Cross validation was performed in
the same fashion for SVM (Table S1 shows the best values
obtained for the metaparameters). Once the optimal metapara-
meters were selected, final RF (RF variable importance of PP_desc
descriptors are listed in Table S2, and for MDL Public Keys in
Table S3), SVM, and NB models were generated using the
complete set of 1,064 molecules in the training dataset. This
process of metaparameter determination and model building was
performed for each pair of three different classifiers (RF, SVM,
and NB) and five molecular representations (PP_desc, Atom
Counts, ECFP_4, FCFP_4, and MDL Public Keys), resulting in a
total of 15 different classification exercises.
Model Benchmarking
Once the training step was finished, we needed to evaluate what
pair of classifier and representation gave the best results on the test
set, consisting of an additional 6,422 metabolites as well as 6,422
non-metabolites that were not used at any stage during model
training. To evaluate model performance we used sensitivity and
specificity values derived from the confusion matrices, together
with ROC curves and their associated AUC. After applying the
models to the test set, the final step involved classification of the
molecules contained to the prospective, external validation sets
described above. The distribution of the metabolite-likeness scores
for these datasets as well as the percentage of correctly classified
compounds are discussed in the Results and Discussion section.
Results and Discussion
PCA and Hierarchical Clustering
PCA was performed to the training set and the loadings and
scores plots for the first four dimensions are presented in Figure 1.
For this PCA, we focus on physicochemical properties (PP_desc)
for the sake of interpretability (PCA results for MDL Public Keys
are presented in Figure S1 and Figure S2, and the percentage of
variance explained in Table S4). Almost 71% of the variance is
explained in the first four components. A slight separation between
metabolites and non-metabolites can be observed in the score plots
of PP_desc (Figure 1A and Figure 1C). The loadings plots for
PP_desc (Figure 1B and Figure 1D) one can see which variables
are correlated or inversely correlated with each class of
compounds. For the first two dimensions (Figure 1B), the variables
that contribute the most to the variance are Molecular Solubility,
Molecular Weigh, Molecular Polar Surface Area (PSA), and the
number of carbon atoms per molecule (C_Count). Metabolites
hence tend to have higher water solubility, lower molecular
weight, and fewer carbon atoms than non-metabolites. These
observations are in accordance to the work of Nobeli et al. [27]
and Dobson et al. [30], who concluded that metabolites are
hydrophilic and have less heavy atoms than non-metabolites. PSA
tends to be bigger than the one of non-metabolites, suggesting that
Metabolite Space and Metabolite-Likeness
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metabolites do not penetrate cell membranes as efficiently as the
non-metabolites. Furthermore, the loadings plot for the third and
fourth dimensions (Figure 1D), shows that the most contributing
variables are Num Rings, Num Rotatable Bonds, N Count, S
Count, and Minimized Energy. The number of rings, rotatable
bonds, and minimized energy, for which metabolites obtain lower
values than non-metabolites, are indicators of molecular complex-
ity, and, therefore, one can conclude that metabolites have simpler
chemical structures than non-metabolites. Interestingly, metabo-
lites also have fewer nitrogen and sulfur atoms than non-
metabolites, as is the case for all atom types except for oxygen
and phosphor, which are more frequent for metabolites as
opposed to non-metabolites.
The results of the PCA of PP_desc and MDL Public Keys were
subject to hierarchical clustering. (Plots are presented in Figure S3.)
In both cases the optimal cluster split, according to the loss of intra-
cluster inertia, returned 3 clusters. The distribution of metabolites
and non-metabolites in each cluster is listed in Table 2. It can be
seen that for PP_desc and MDL Public Keys 2 large clusters and a
third small one are formed, each of them containing one dominant
class of compounds. The first cluster for PP_desc has a purity of
70.2% (370 metabolites and 157 non-metabolites), the second
cluster has a purity of 89.65% (52 metabolites and 6 non-
metabolites), and the third cluster has a purity of 77.03% (110
metabolites and 369 non-metabolites). Using MDL Public Keys, the
first cluster has a purity of 78.81% (372 metabolites and 100 non-
metabolites), the second cluster has a purity of 73.03% (134
metabolites and 363 non-metabolites), and the third cluster has a
purity of 72.63% (26 metabolites and 69 non-metabolites).
However, the purity of each cluster is not high and this, together
with the lack of separation observed in the PCA, leads us to think
that the separation of metabolites from non-metabolites requires the
utilization of more sophisticated methods like random forests, or
other nonlinear classifiers as explored in the following.
Fingerprint Features and Fragment Analysis
A classification tree was built upon the training set, which was
described using non-hashed ECFP_4 fingerprints (Figure 2). The
Figure 1. Principal Components Analysis of the PP_desc training set. PCA plots (A,C) and variable contributions(B,D) for the training datasets
PP_desc.
doi:10.1371/journal.pone.0028966.g001
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results give a general idea of which chemical moieties are
characteristic of each class of compounds. As expected, the most
discriminating feature was the hydroxyl group, in agreement with
the work by Gupta et al. [28], with a higher frequency among
metabolites. On the other hand, the presence of chemical moieties
containing nitrogen, in particular secondary amines and secondary
imines, is highly correlated with a class membership of the non-
metabolites. Finally, in the case a molecule lacks hydroxyl
functionalities (demonstrated to be metabolite-like moieties), but
it also lacks five or three member rings, ether-like features, and
primary amines, it will likely be a metabolite (which is the
combination of features in the left-most branch of the tree in
Figure 3).
When looking at the frequent fragments of metabolites (Figure 3)
and non-metabolites (Figure 4), we corroborate this finding.
Among metabolites, hydroxyls and carboxylic acids are frequent as
well as rings containing oxygen atoms. In the case of non-
metabolites, either rings or linear fragments containing nitrogen
and sulfur abound, which is in accordance to the classification tree
results, in accordance to the findings of Hert et al. [64]. Other
frequent fragments of metabolites are the phosphate group,
characteristic of some classes of metabolites like nucleotides and
phospholipids, as well as the steroid and adenine scaffolds. This
importance of class-specific fragments can make two metabolites
from different classes very different, and it hence poses a challenge
when building models that aim to capture such diversity within a
given class. One option is to build local models for each subclass of
metabolites; but in this study we aimed at building a global model
for metabolites, and as a result, we rely on complex classifiers to
predict the metabolite-likeness of molecules. These classification
models were built using the methods and data described in the
methods section and they were applied to our test set.
Test Set
In this study we used 5 molecular representations and 3
classifiers. Our aim was to select which combination of molecular
representation and classifier yielded the best classification results
for metabolites. The classification results on the test set for each
combination are presented in Table 3 and visualized graphically in
Figure 5. MDL Public Keys and RF, reporting 99.84% sensitivity
and 88.79% specificity, achieve best results. ECFP_4 is the best
performing molecular representation when used with SVM,
achieving 99.55% sensitivity, while PP_desc achieves the highest
AUC of 98.66%. MDL Public Keys also outperformed the other
representations for NB, with a sensitivity of 96.71%, specificity of
86.97%, and an AUC of 97.99%. Another representation that
exhibits a solid performance across the whole study is ECFP_4
(which is in line with previous studies [65,66]). This fingerprint has
the best sensitivity for SVM, 99.55%, the second best AUC for
RF, 99.07%, and the second best sensitivity, 97.15%, and AUC,
94.25% for NB. A conceptually related fingerprint, namely
FCFP_4, shows surprisingly worse performance than MDL Public
Keys and ECFP_4 fingerprints by having smaller AUC values for
RF, SVM, and NB, 98.16%, 94.19%, and 80.80% respectively.
Molecular descriptors, both PP_desc and Atom Counts, perform
well: PP_desc reports better AUC for RF and SVM, 98.93% and
98.66% respectively, than FCFP_4, 98.13% and 94.19% respec-
tively. Atom Counts descriptors also outperform FCFP_4 in SVM
in terms of AUC, 98.02% the former and 94.19% the latter. On
Table 2. Cluster distribution of the molecules in the training
datasets, using PP_desc and MDL Public Keys.
Cluster Type PP_desc MDL Public Keys
1 HMDB 370 372
1 ZINC 157 100
2 HMDB 52 134
2 ZINC 6 363
3 HMDB 110 26
3 ZINC 369 69
The clustering performed was a hierarchical clustering and the dendogram was
cut at the point of maximal inertia loss.
doi:10.1371/journal.pone.0028966.t002
Figure 2. Conditional inference tree of the ECFP_4 features in the training set. Hydroxyls, carboxylic acids, and linear structures are
associated with metabolites, whereas secondary amines and secondary imines are associated with non-metabolites.
doi:10.1371/journal.pone.0028966.g002
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Figure 3. Top 20 most frequent fragments in HMDB. The 20 most frequent ring systems, chain assemblies, and Murcko assemblies in the
metabolite data set (HMDB compounds). ‘H’ refers to the frequency of fragments in the HMDB dataset, ‘Z’ to the frequency of fragments in the ZINC
dataset. Fragments with less than 4 heavy atoms were excluded. Oxygen containing rings, phosphate group, hydroxyl, carboxylic acid, and the
steroid scaffold, among others, are common fragments in metabolites.
doi:10.1371/journal.pone.0028966.g003
Figure 4. Top 20 most frequent fragments in ZINC. The 20 most frequent ring systems, chain assemblies, and Murcko assemblies among the
ZINC compounds, here chosen as a non-metabolite-like set. ‘H’ refers to the frequency of fragments in the HMDB dataset, ‘Z’ to the frequency of
fragments in the ZINC dataset. Fragments with less than 4 heavy atoms were excluded. Nitrogen containing rings dominate the most frequent
fragments.
doi:10.1371/journal.pone.0028966.g004
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the other hand, PP_desc and Atom Counts underperformed when
used with NB, where the AUC obtained was 61.57% and 58.95%,
respectively.
By looking at the average AUC results for the different
representations we conclude that MDL Public Keys (with
98.19%) and ECFP_4 (with 97.18%) are the best performing
representations overall. If we observe the average results obtained
by the classifiers, RF outperforms SVM and NB in each category
with averages of 99.26% sensitivity, 87.41% specificity, and
98.52% AUC.
From the results presented in this work we see that with the
optimal combination of molecular descriptors and classifier, MDL
Public Keys and RF, 99.84% of the metabolites and 88.79% of the
non-metabolites in the test set are classified correctly. These results
are slightly better than those presented by Gupta et al. [28], who
reported 97% correct predictions for KEGG metabolites using RF
and global molecular descriptors, which are similar to the PP_desc
descriptors used in the current work. While these 97% correct
predictions were achieved on the dataset used to train the model,
our 99.84% correctly classified metabolites were not employed in
training the model. Interestingly, it is also observed in our
predictions that metabolites have a smaller false positive rate than
non-metabolites, which reinforces the idea that it is easier to
determine what makes a metabolite a metabolite, than what makes a
non-metabolite a non-metabolite. The ZINC molecules that have
been classified as metabolites (some of them shown in Figure S4),
form an interesting set for further research, since according to the
models they exhibit metabolite-like features, which would give
them an increased likelihood of being bioactive in experimental
screening [64].
With respect to the classification algorithms, RF and SVM have
demonstrated their status as the ‘state of the art’ in machine
learning, as applied to this dataset. This good performance comes
however at the expense of having to optimize metaparameters,
which is more demanding for SVM, where finding the right
gamma and cost results in changing the value ranges multiple
times. From this experience, when facing a classification problem
where objects are described by a large number of variables and
only a modest computational power is available, RF is a good
compromise.
As seen in previous research, ECFP_4 is a solid ‘all-round
performer’ [65,66], which obtains good results in combination
with the different classification approaches. The most surprising
feature is that with simpler molecular representations than
ECFP_4, like MDL Public Keys or PP_desc molecular descriptors,
one can achieve similar or slightly improved results from the
above, as it has been observed before [67]. This finding confirms
the idea that (at least known) ‘Metabolite Space’ is a well-defined
subset of all ‘Chemical Space’, and that hence its diversity can be
modeled with success using either 1D or 2D descriptors.
Apart from the discussion of general model performance we also
investigated cases where our model failed, which may be either
due to wrong data annotation or wrong predictions of the model.
Figure 6 depicts false negative predictions, i.e. those metabolites
with a metabolite-likeness value of 50% or lower, and which were
therefore being considered as non-metabolites in combination with
the MDL Public Keys and the RF classification method. Although
these molecules would be considered non-metabolites by our
model, 9 out of 10 obtain a metabolite-likeness of 40% or more. It
is interesting to note that the lowest scoring compound,
debrisoquine with a score of 35.4%, is in fact a drug. Since it
was not described as such by the HMDB taxonomy, our filtering
step did not eliminate it. The same occurs for entacapone, which is
a drug and has a predicted metabolite-likeness of 48.8%.
Nevertheless, our classification method was able to assign to both
drugs the lowest metabolite-likeness scores. Non-endogenous
compounds are also present in this group of compounds, such as
nicotine glucuronide, and 4b-Hydroxystanozolol, a metabolite of
Table 3. Classification results of the test set.
Random Forest SVM Naı¨ve Bayes Average
Sensitivity Specificity AUC Sensitivity Specificity AUC Sensitivity Specificity AUC Sensitivity Specificity AUC
PP_desc 99.17% 88.60% 98.93% 96.82% 88.93% 98.66% 42.51% 86.56% 61.57% 79.50% 88.03% 86.39%
Atom Counts 97.91% 85.57% 97.33% 98.05% 84.10% 98.02% 36.66% 92.90% 58.95% 77.54% 87.52% 84.77%
ECFP4 99.80% 86.27% 99.07% 99.55% 83.43% 98.23% 97.15% 83.29% 94.25% 98.83% 84.33% 97.18%
FCFP4 99.55% 87.84% 98.16% 81.89% 86.53% 94.19% 99.75% 44.80% 80.80% 93.73% 73.06% 91.05%
MDL 99.84% 88.79% 99.13% 98.54% 86.48% 97.45% 96.71% 86.97% 97.99% 98.36% 87.41% 98.19%
Average 99.26% 87.41% 98.52% 94.97% 85.90% 97.31% 74.56% 78.90% 78.71% 89.59% 84.07% 91.52%
Results for the test set, including the percentage of correctly classified metabolites (Sensitivity), the percentage of correctly classified non-metabolites (Specificity) and
the Area Under the Curve (AUC). It can be observed that the best combination of descriptor and classifier is MDL Public Keys and Random Forest and that the second
best is ECFP_4 fingerprints and Random Forest. Interestingly, physicochemical descriptors (PP_desc) perform well both with Random Forest and Support Vector
Machines classifiers. (A molecule is considered metabolite if its metabolite-likeness .50%).
doi:10.1371/journal.pone.0028966.t003
Figure 5. Classification accuracy on the test set. Percentage of
correctly classified molecules of the test set for each combination of
fingerprint and classifier. Sensitivity is in most cases larger than 90%,
except for FCFP_4 and SVM, and Atom Counts and PP_desc and NB.
Specificity is larger than 80% in most cases, except FCFP_4 and NB. It
can be observed that metabolites are classified more accurately than
non-metabolites when using RF and SVM.
doi:10.1371/journal.pone.0028966.g005
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the synthetic anabolic steroid stanozolol. In the same fashion, we
find in this set vanillylamine, with 49% of predicted metabolite-
likeness, which is a metabolite of the natural product Vanillin and
which structure resembles the endogenous metabolite 4-Methox-
ytyramine, which obtains a metabolite-likeness score of 48.8%.
Unfortunately, some endogenous metabolites like Uroporphyrin
II, 3-Methylhistamine, Melatonin, and Vitamin K1 2,3-epoxide,
received a low score without an obvious reason, and they are
hence false-negative predictions of our model.
Prospective Validation
Three prospective datasets containing metabolites, drugs, and
small molecules, were next classified using our two best performing
models, using RF and either MDL Public Keys or PP_desc. The
results are displayed in Table 4 and indicate that 95.84% of the
new metabolites (obtained after model training has been finished)
are correctly classified as metabolites, indicating the generalizabil-
ity of our model to classify new data. As for the drugs (represented
by DrugBank compounds), 54.37% are assigned a metabolite-
likeness of 50% or higher, which is in accordance with our
assumption that many drugs indeed resemble metabolites (as has
been presented before [64]). For the third dataset, the screening
compounds from ChEMBL, molecules predicted to be metabolites
only represent 22.39% of the total dataset, hence a smaller
percentage than for drugs. In Figure 7 the distributions of
metabolite-likeness for each dataset are visualized. We see that
most of the new HMDB compounds (HMDB_unofficial) show
high values of metabolite-likeness, while the ChEMBL molecules
give values that are accumulating at the lower-scoring end of the
distribution. The DrugBank molecules on the other hand are
evenly distributed among all the metabolite-likeness ranges, with
slight peaks at both the metabolite-like, as well as the non-
metabolite-like end of the spectrum. This result is in accordance to
the work of Ertl et al. [68], where a Natural Product-Likeness
score was reported after studying natural products, drugs, and
screening compounds. Natural products are molecules produced
by living organisms, and therefore they can be regarded as to some
extend similar to the human metabolites we employed in our work.
Ertl et al. concluded that drugs are more similar to natural
products than screening compounds, a similar finding to what we
have presented. This biogenic bias is also present in screening
libraries, as presented by Hert et al. [64]; however, the wide spread
of drugs along the spectrum of metabolite-likeness (in particular
with slight peaks at either end of the scale) has not been previously
reported.
While numerical performance is one thing, the chemical
interpretation of model predictions remains crucial. Hence, in
order to explore further the results of the prospective validation,
molecules of the three different classes (metabolites, drugs,
bioactive compounds), which fall into different bins of metabo-
lite-likeness scores, are presented in Figure 8. The first noticeable
feature is the absence of a metabolite with a predicted metabolite-
likeness smaller than 10%, underlining the homogeneity of
metabolites as a class (as opposed to non-metabolites). As a matter
of fact, the metabolite HMDB13193 obtained the lowest
metabolite-likeness, 17%, contains two chlorine atoms, which is
not common in metabolites. Another interesting situation occurs
with molecules that have a steroid scaffold, a common fragment in
endogenous metabolites. Metabolite HMDB12524 and drug
DB00180 (flunisolide) obtain metabolite-likeness values of 60.6%
and 52%, respectively. Here flunisolide possesses a fluorine atom,
which is not frequent in metabolites, and which might have hence
reduced its metabolite-likeness score. Conversely, ChEMBL
compound CHEMBL1163241 also has the steroid scaffold but
obtains a score of just 35.2% on the metabolite-likeness scale,
corresponding related to having two fluorine atoms and a
secondary amine, features that the classification tree revealed
to be common in non-metabolites. Finally, examples of com-
pounds with high values of predicted metabolite-likeness are
DB00131 (adenosine monophosphate), DB00125 (L-arginine),
CHEMBL6422, and CHEMBL14568, which receive 84.2%,
99%, 82.8%, and 96.8% respectively. Adenosine monophosphate
includes the phosphate group, frequently found in metabolites
together with two hydroxyl groups. Metabolite-likeness features of
Figure 6. Metabolites in the test set predicted as non-
metabolites. The 10 only false negative metabolites from the test
set. These metabolites obtained a Metabolite-likeness score smaller
than 50%, therefore being classified as non-metabolites, using the best
model, MDL Public Keys and Random Forest. Debrisoquine obtains the
lowest score; it is a drug that was not taxonomically described as such.
9 out of 10 compounds have 40% or more metabolite-likeness, which is
very close to our cut-off used to predict metabolites.
doi:10.1371/journal.pone.0028966.g006
Metabolite Space and Metabolite-Likeness
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28966
L-Arginine, like linearity and a carboxylic group, outweigh the
non-metabolite features like the nitrogen containing functional
groups. Compound CHEMBL6422 possesses a carboxylic acid
and hydroxyl functionalities, while and CHEMBL14568 is small,
linear, and also exhibits a hydroxyl group, leading to a very high
metabolite-likeness score.
The results obtained from the prospective validation demon-
strate that our model is successful at identifying whether a
molecule is a metabolite or not, which we expect to help studies
that involve metabolite identification in the future. Furthermore,
metabolite-likeness helps to detect non-metabolites that exhibit
features characteristic of metabolites, which can be of interest for
drug discovery In our future work, we will explore both of those
avenues with results to be communicated shortly.
In this work we evaluated various machine-learning models with
respect to their ability to discriminate metabolites from non-
metabolites, and hence, to calculate the metabolite-likeness score of
a given molecule. Our best model detects 99.84% of the metabolites
from the test set and 95.84% of the metabolites from a prospective
validation set, hence underlining the applicability of the classifier to
the majority of novel metabolites. While we confirm that drugs are,
on average, more metabolite-like than other compound classes, we
noted a considerable spread of drugs across the metabolite-likeness
spectrum, with two small (but distinct) peaks at either end of the
spectrum, illustrating that both synthetic molecules and metabolite-
like compounds may become successful drugs. As for the application
side, metabolite-likeness is a tool to rank compounds that ‘need’ to
resemble metabolites, which may be (as above) certain types of
Table 4. Percentage of molecules classified as metabolites or
non-metabolites for three independent sets.
RF Prediction
Metabolites Non-Metabolites
HMDB_unofficial 95.84% 4.15%
DrugBank 54.37% 45.62%
ChEMBL 22.39% 77.61%
95.84% of independent metabolites are correctly classified. More than half of
the drugs in DrugBank are considered metabolites. Only 22.39% of the
screening compounds in ChEMBL are predicted as metabolites. (A molecule is
considered metabolite if its metabolite-likeness .50%.).
doi:10.1371/journal.pone.0028966.t004
Figure 7. Metabolite-likeness distribution of the prospective validation sets. Distribution of predicted metabolite-likeness for the three
classes of molecules in the prospective evaluation set using our best predicting model, RF and MDL Public Keys (namely metabolites from HMDB,
drugs from DrugBank and bioactive compounds from ChEMBL). Most of the metabolites are predicted at a metabolite-likeness of 60% or higher. Most
of non-metabolites from ChEMBL obtain low values. Drugs from DrugBank are spread across the whole range of values, with higher concentrations at
both ends, which indicate a presence of synthetic drugs, for low values, and metabolite-like drugs at high values.
doi:10.1371/journal.pone.0028966.g007
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drugs, but also in particular candidate structures in metabolite
identification. Given the performance of our model, we will now
continue with our work to apply our model in precisely those areas.
Accordingly, we expect to use this tool in metabolomics studies
where no database match is found for the unknown compound and
therefore, candidate structures are generated based on mass
spectrometry data, e.g. elemental composition, using a structure
generation tool. These output molecules would be then ranked
according to their Metabolite-Likeness. Furthermore, we have also
studied which functional groups, fragments, and physicochemical
properties help describe the Metabolite Space. Our findings give a
general idea of what metabolites look like, but also encourage us to
look closer at the different subclasses of metabolites and to explore
the applicability of a local model approach if we want to expand our
knowledge of metabolites.
Supporting Information
Figure S1 PCA of the PP_desc andMDL Public Keys that
the RF model considers important. The importance
criterion is the Mean Decrease Accuracy. The separation of both
classes is slightly improved for PP_desc using these important
variables if compared with the PCA score plot in Figure 1.
(TIF)
Figure S2 PCA of the PP_desc andMDL Public Keys that
the RF model considers important. The importance
Figure 8. Molecules of the prospective validation sets with different predicted metabolite-likeness values. Compounds of the 3 classes
present in the prospective evaluation set using our best predicting model, RF and MDL Public Keys, sorted according to their predicted metabolite-
likeness. Non-metabolite compounds exhibit moieties characteristic of metabolites like carboxylic acids and phosphate groups, which make them
obtain high values of metabolite-likeness.
doi:10.1371/journal.pone.0028966.g008
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criterion is the Mean Decrease Gini. The separation of both
classes is slightly improved for PP_desc using these important
variables if compared with the PCA score plot in Figure 1.
(TIF)
Figure S3 Hierarchical clustering of PP_desc and MDL
Public Keys. Plots of the first two dimensions of the Hierarchical
Clustering. For PP_desc: A, using all variables; B, using the
important variables according to Accuracy decrease; C, using the
important variables according to Gini decrease. For MDL Public
Keys: A, using all variables; B, using the important variables
according to Accuracy decrease; C, using the important variables
according to Gini decrease. In all cases the optimal cut of the
dendogram, according to the maximum loss of inertia, returns 3
clusters.
(TIF)
Figure S4 Non-metabolites predicted as metabolites.
Some non-metabolites from the test set that obtained a
Metabolite-likeness score greater than 50%, therefore being
classified as metabolites, using the best model, MDL Public Keys
and Random Forest. These are the 20 cluster centers selected from
the clustering performed on all the false positives.
(TIF)
Table S1 Optimal metaparameters for classifiers. mtry for
Random Forest, Gamma and Cost for Support Vector Machines,
obtained after performing Cross Validation on the training set.
(DOC)
Table S2 Importance given to the PP_desc descriptors by
Random Forest. High values on Mean Decrease Accuracy and in
Mean Decrease Gini indicate that this variable is important to
discern between metabolites and non-metabolites. These impor-
tance values have been obtained from the Random Forest model
built with the training set.
(DOC)
Table S3 Importance given to the MDL Public Keys by
Random Forest. High values on Mean Decrease Accuracy and
in Mean Decrease Gini indicate that this variable is important to
discern between metabolites and non-metabolites. These impor-
tance values have been obtained from the Random Forest model
built with the training set.
(DOC)
Table S4 Cumulative percentage of variance explained of the
first 8 principal components. PCA was performed on the Atom
Counts, PP_desc, and MDL Public Keys datasets.
(DOC)
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